| Literature DB >> 24696260 |
Anna Pryczynicz1, Katarzyna Guzińska-Ustymowicz, Katarzyna Niewiarowska, Dariusz Cepowicz, Andrzej Kemona.
Abstract
E-cadherin, a transmembrane adhesion molecule, and phosphatase of regenerating liver 3 (PRL-3) protein, a member of the family of tyrosine phosphatases, seem to be responsible for cancer cell migration. Therefore, the study objective was to determine a correlation between PRL-3 and E-cadherin, to assess their expression in neoplastic tissue and normal mucosa of the stomach, to analyze their effect on cancer advancement, and to evaluate their potential as prognostic markers in gastric cancer. The expressions of PRL-3 and E-cadherin were assessed immunohistochemically in 71 patients with gastric cancer. Positive expression of PRL-3 was observed in 42.2 % of gastric cancer cases, whereas E-cadherin expression was abnormal in 38 % of cases. The study revealed that the positive PRL-3 expression and abnormal E-cadherin expression were associated with mucinous gastric carcinoma and lymph node involvement. The former was also related to the infiltrating type of tumor and abnormal E-cadherin expression. The expression of PRL-3, but not of E-cadherin, was associated with shorter survival of patients. PRL-3 and E-cadherin exhibit interactions in gastric cancer and are involved in the formation of lymph node metastases. The PRL-3 protein can be an independent predictive factor of overall survival in gastric cancer patients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24696260 PMCID: PMC4107272 DOI: 10.1007/s13277-014-1855-7
Source DB: PubMed Journal: Tumour Biol ISSN: 1010-4283
Fig. 1Immunohistochemical staining. a PRL-3 expression in the gastric mucosa. b Positive cytoplasmic PRL-3 reaction in gastric cancer cells. c Cytoplasmic membrane expression of E-cadherin in the gastric mucosa. d Negative of E-cadherin expression in gastric cancer cells. Original magnification: ×200 and ×400
Relationship between the expressions of PRL-3 and E-cadherin proteins and clinicopathological parameters in gastric cancer
| Variables | PRL-3 expression |
| E-cadherin expression |
| ||
|---|---|---|---|---|---|---|
| Absent | Present | Abnormal | Normal | |||
| Age | ||||||
| ≤ 50 | 10 | 10 | 0.415 | 12 | 12 | 0.358 |
| > 50 | 31 | 20 | 15 | 32 | ||
| Gender | ||||||
| Male | 28 | 21 | 0.880 | 21 | 30 | 0.591 |
| Female | 13 | 9 | 6 | 14 | ||
| Location | ||||||
| Upper 1/3 | 2 | 4 | 0.114 | 1 | 1 | 0.568 |
| Middle 1/3 | 16 | 14 | 14 | 16 | ||
| Lower 1/3 | 23 | 12 | 13 | 26 | ||
| Depth of invasion | ||||||
| T1 | 5 | 1 | 0.114 | 1 | 5 | 0.794 |
| T2 | 11 | 6 | 6 | 8 | ||
| T3 | 25 | 23 | 21 | 30 | ||
| Histological differentiation | ||||||
| Moderately differentiated | 20 | 9 | 0.115 | 12 | 23 | 0.585 |
| Poorly differentiated | 21 | 21 | 15 | 21 | ||
| Hp | ||||||
| Adenocarcinoma | 36 | 17 |
| 21 | 42 |
|
| Adenocarcinoma mucinosum | 5 | 13 | 10 | 5 | ||
| Goseki’s classification | ||||||
| I | 7 | 4 | 0.254 | 3 | 5 | 0.188 |
| II | 8 | 10 | 9 | 11 | ||
| III | 5 | 5 | 6 | 5 | ||
| IV | 14 | 18 | 17 | 13 | ||
| Lauren’s classification | ||||||
| Intestinal type | 31 | 16 | 0.051 | 16 | 35 | 0.086 |
| Diffuse type | 10 | 14 | 11 | 9 | ||
| Borrmann’s classification | ||||||
| I (polypoid) | 4 | 1 |
| 3 | 4 | 0.935 |
| II (fungating) | 8 | 4 | 8 | 13 | ||
| III (ulcerated) | 26 | 17 | 19 | 27 | ||
| IV (infiltrative) | 3 | 8 | 7 | 10 | ||
| Lymph node metastasis | ||||||
| Absent | 40 | 9 |
| 10 | 45 |
|
| Present | 1 | 21 | 17 | 1 | ||
|
| ||||||
| Absent | 16 | 18 | 0.373 | 15 | 20 | 0.320 |
| Present | 20 | 17 | 12 | 24 | ||
| E-cadherin expression | ||||||
| Abnormal | 9 | 14 |
| – | – | – |
| Normal | 28 | 10 | ||||
Significant relationship is marked in italics
Missing data were removed in pairs
Fig. 2Postoperative overall survival of patients with gastric cancer. Comparison of postoperative survival according to the expressions of PRL-3 and E-cadherin
Univariate and multivariate analysis of clinicopathological factors in gastric cancer
| Variables | Univariate | Multivariate | Hazard ratio | 95 % CI |
|---|---|---|---|---|
| Age (≤50 vs. >50) | 0.081 | – | 1.600 | 0.942–2.715 |
| Gender (male vs. female) | 0.641 | – | 1.137 | 0.660–1.959 |
| Location (upper 1/3, middle 1/3, vs. lower 1/3) | 0.873 | – | 1.042 | 0.627–1.730 |
| Depth of invasion (T1, T2, vs. T3) |
| 0.078 | 1.852 | 1.008–3.403 |
| Histological differentiation (moderately diff. vs. poorly diff.) | 0.641 | – | 1.145 | 0.646–2.029 |
| Hp (adc. vs. adc. mucinosum) |
|
| 0.293 | 0.127–0.678 |
| Goseki’s classification (I and III vs. II and IV) | 0.864 | – | 1.073 | 0.476–2.419 |
| Lauren’s classification (intestinal type vs. diffuse type) |
|
| 2.422 | 1.140–5.143 |
| Borrmann’s classification (I and II vs. III and IV) | 0.068 | – | 0.587 | 0.331–1.040 |
| Lymph node metastasis (absent vs. present) | 0.372 | – | 0.705 | 0.327–1.519 |
|
| 0.713 | – | 1.109 | 0.635–1.937 |
| PRL-3 expression (absent vs. present) |
|
| 4.059 | 1.615–10.198 |
| E-cadherin expression (abnormal vs. normal) | 0.318 | – | 0.713 | 0.367–1.384 |
Significant relationship is marked in italics
Borrmann’s classification: I (polypoid), II (fungating), III (ulcerated), and IV (infiltrative)
diff. differentiated, adc. adenocarcinoma, CI confidence interval